Lupin Ltd.'s attractive valuation now reflects its robust fundamentals and promising pharmaceutical growth prospects. The shift signifies investor confidence in the company's continued success in the industry.

Lupin has secured China's approval for its flu drug Oseltamivir Phosphate oral suspension, marking their first venture in the Chinese market. This pediatric flu treatment will bolster their focus on children's health. Partnering with Yabao Pharma is expected to strengthen their market presence.

Pharmaceutical company Lupin has gained approval from Chinese regulators to sell their antiviral drug, oseltamivir phosphate oral suspension, in the country, expanding their market reach.

Coforge spearheaded a significant increase in ODI investments, totaling $2.37 billion in April '26. This surge primarily reflects an emphasis on equity focus, with Lupin, Wingify, and other companies collectively accounting for 86% of these investments, pushing the overall ODI to $3.37 billion.

Bernstein has recommended investing in Zydus, Lupin, and Sun Pharma, predicting a potential $75 billion growth in India's biopharmaceutical sector over the next decade. The firm believes that innovation, AI integration, and focus on niche therapies could propel this growth, with Zydus being their top choice. Biocon and Mankind Pharma were rated as less promising investments.

Lupin has received a tentative approval from the US FDA for refevenacin inhalation solution, opening up promising opportunities for its presence in the US market. This move bolsters Lupin's potential to commercialize products within the United States.

Lupin has received a preliminary approval from the FDA for their COPD drug Revefenacin, which matches the effectiveness of Mylan's Yupelri (worth $260.7M annually in US sales). This move could potentially increase competition and lower costs for consumers in the COPD treatment market.

Pharmaceutical company Lupin made a significant block trade on the NSE, exchanging over 76,000 shares at approximately Rs. 2,286 each, amounting to around Rs. 17.5 crore.

Lupin has secured FDA approval for its ulcer drug, Famotidine Injection USP, which is equivalent to Merck's Pepcid. This move allows them to target an estimated $8.7 million market in the U.S., primarily for treating ulcers, GERD, and hypersecretory conditions.

Lupin Limited has obtained FDA approval for their famotidine injection, enhancing their position in the U.S. acute care market with branded generic products. This move is expected to boost their presence in the American pharmaceutical market.

Lupin has received approval from the US FDA to market Famotidine Injection in the United States, expanding their product portfolio with this antacid medication.

Notable stocks in the spotlight today are sugar exporters, dairy manufacturers, NBCC, Zydus Life, Lupin, Bajel Projects, and Zaggle. These companies have generated significant interest among investors. Keep an eye on their market trends for potential opportunities.

India has imposed a sugar export ban until September 2026, potentially affecting companies like Balrampur Chini, Bajaj Hindustan, and Triveni Engineering due to production shortages. Meanwhile, NBCC secured ₹131 crore worth of projects, Zydus acquired Assertio for ₹1,592 crore, Bajel Projects won ₹500 crore Power Grid orders, and Lupin received USFDA approval for Famotidine Injection.

Lupin Ltd.'s open interest increased by 18%, reaching 56,371 contracts, suggesting a growing bullish sentiment in the market despite mixed sector performances.

Nomura keeps a bullish stance on Lupin, setting a target price of INR 2,580. The company's earnings have surpassed expectations, with promising growth in Indian formulations and potential improvement in US revenue.

Investment firm Prabhudas Lilladher has suggested buying Lupin shares, setting a target price at ₹2,500. This recommendation comes from their recent report dated May 11, 2026.

Lupin's share price dropped by 4.9% today following Nuvama's downgrade to 'Hold', lowering their target price to Rs 2,600 from Rs 2,550. Despite the downgrade, Nomura remains optimistic, maintaining a 'Buy' rating and setting a target price of Rs 2,580. Lupin's shares have shown a positive trend over the past six months, rising by 14.5%.

Lupin experienced a 3.9% decline in share price with an increased trading volume five times higher than its usual, indicating significant selling pressure. In contrast, momentum stocks like Niva Bupa, Tata Consumer, and Kalpataru recorded gains of up to 5%, although other stocks saw losses for the day.

Titan and Kalyan Jewellers experience a decline following the Prime Minister's appeal, while SBI and Lupin suffer heavy losses post-results. Siemens may be affected by ABB, and InterGlobe Aviation experiences a drop, contrasted by Voda Idea's surge on specific news reports.

Lupin anticipates a tax rate of 25-26% for the upcoming fiscal year, given the reduction in incentives. The company expects US revenue to surpass $1 billion, despite stiff competition, due to projected growth and new product launches offsetting potential losses.

Lupin aims for a healthy single-digit revenue increase in the fiscal year 2027, concurrently striving for 25% EBITDA margins. Despite competition in mirabegron, tolvaptan, and higher R&D expenditure, the company remains optimistic about its future growth trajectory.

Systematix lowers Lupin's target price to INR 2,408 due to increasing competition in key products like gTolvaptan and gMirabegran by FY27. Q4 FY26 earnings showed a 32% year-on-year growth but quarter-over-quarter declines. Lupin's future performance hinges on the approvals of biosimilars and respiratory inhalers.

CLSA continues to endorse Lupin with a target price of ₹2690, driven by impressive Q4FY26 results from its US business and domestic growth. The company anticipates high-single to low-double-digit revenue growth in FY27, along with a 25% EBITDA margin and approximately 80 new product launches.

For investors seeking guidance on May 11, consider SBI, Titan, Lupin, and Tata Consumer. Recommendations vary from buying, selling, to holding, offering a diverse range of options for each stock. Stay updated with market trends for informed investment decisions. (ET NOW)

Elara Capital has lowered its rating for Lupin to 'Reduce', suggesting potential investors consider other opportunities, with a revised price target of ₹2,447.

Titan receives upgrades from HSBC and JPMorgan due to strong Q4 performance and jewelry growth, with new target prices set at Rs 4,930-5,400. Meanwhile, SBI, Hyundai, Lupin, and Swiggy experience mixed broker ratings, as analysts weigh growth potential, industry trends, and macroeconomic challenges.

Pharmaceutical stocks are surging today, with increased demand for shares in companies like Thermax, Thyrocare, and Vijaya Diagnostics. However, Lupin's stock is down despite reporting positive results, while Britannia experiences a drop due to weak earnings. Sterlite Tech, on the other hand, is seeing an uptick.

Lupin's U.S. operations have surpassed expectations, thanks to successful new product launches that contributed significantly to Q3 profits. CEO Vinita Gupta emphasized these key launches as significant factors behind the strong performance.

Pharma company Lupin aims to achieve $1 billion in US sales by FY27, primarily through the expansion of biosimilars and specialty products. The GLP-1 segment is gaining momentum in India following a partnership with Zydus, and Lupin also plans acquisitions in strategic markets.

Lupin Ltd. achieves new highs in Q4 2026 with impressive revenue, profits, and a Mojo Score of 87.0. Investment analysts have upgraded their recommendation for the company to 'Strong Buy', reflecting optimism about its future performance.

Today marks the release of Q4 results for major companies including SBI, Titan, ABB India, BoB, MCX, Biocon, Dabur, Lupin, and MRF. Stocks to watch out for include Ujjivan Small Finance Bank, Kalyan Jewellers, BSE, KVB, TCP, ACME, with Hyundai and Swiggy also gaining attention.

Lupin, a pharmaceutical company, anticipates facing margin pressure in the U.S. market, potentially impacting their profits as reported by CNBC. This could be due to increased competition or pricing pressures. Investors should keep an eye on updates from the company regarding this development.

Lupin aims for over 20 product launches in the upcoming fiscal year (FY27) to outpace market expansion. The company is setting its sights on submitting at least 15 abbreviated new drug applications, with a focus on developing complex generics and biosimilars by 2028-2031.

Morgan Stanley maintains a neutral stance on Lupin, predicting a share price of ₹2386, based on the company's impressive Q4 growth in revenue, EBITDA, and PAT. This growth was primarily driven by increased US sales, a 11.5% year-on-year increase in India sales, and a 49% year-on-year rise in emerging market sales, fueled by the success of drugs like gMyrbetriq and gSpiriva.

According to the latest market advice, Dabur India, Britannia, Coal India, Lupin, Bharat Forge, and Aditya Birla Lifestyle stocks may see changes in their positions depending on individual investment plans. It's recommended to evaluate these stocks according to your personal investment strategies.

Lupin's Q4 US sales have reached a new high, which could potentially affect the company's stock value positively due to improved operational performance. The impressive financial results may also attract investor interest, potentially influencing share prices.

Today, BSE, Lupin, Cochin Shipyard, and Suryoday Small Finance Bank are stocks to watch out for, as analysts have shared their perspectives in anticipation of the upcoming trading session. Keep an eye on these companies for potential market movement insights.

Pharma giant Lupin announces a final dividend of INR 18 per share, providing shareholders with additional returns.

Morgan Stanley has kept Lupin's rating at Equal Weight and set a target price of INR 2,386, suggesting potential for modest growth compared to its peers. Investors should monitor Lupin's performance closely in this assessment.

Pharmaceutical company Lupin announces a final dividend of INR 18 per share for the fiscal year ending March 31, 2026 - which represents a significant increase of 900% compared to its face value of INR 2.